Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560837 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EMEN1KMT2ABACE1 | |
| SCHEMBL3846868 | 0.81 | MAPT (0.53) | SMN1; SMN2KDM4EMEN1KMT2ABACE1 | |
| SCHEMBL3561197 | 0.80 | AR (0.48) | SMN1; SMN2KDM4EMEN1KMT2ABACE1 | |
| SCHEMBL3561199 | 0.80 | AR (0.48) | SMN1; SMN2KDM4EMEN1KMT2ABACE1 | |
| SCHEMBL25666676 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4EMEN1KMT2AMAPT | |
| SCHEMBL1805977 | 0.78 | RAB9A (0.64) | SMN1; SMN2KDM4EMEN1KMT2AMAPT | |
| SCHEMBL1805971 | 0.78 | RAB9A (0.64) | SMN1; SMN2KDM4EMEN1KMT2AMAPT | |
| SCHEMBL3562126 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMEN1KMT2AMAPT | |
| SCHEMBL195311 | 0.76 | ALDH1A1 (0.62) | SMN1; SMN2KDM4EKMT2AMAPTNPSR1 | |
| SCHEMBL29084737 | 0.76 | BRAF (0.60) | SMN1; SMN2KDM4EMEN1KMT2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1761486-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000288-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SMN1; SMN2 4522/4885KDM4E 1045/4885MEN1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.